These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34078238)

  • 21. N-terminal pro-brain natriuretic peptide and exercise capacity in chronic heart failure: data from the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study.
    Felker GM; Whellan D; Kraus WE; Clare R; Zannad F; Donahue M; Adams K; McKelvie R; Piña IL; O'Connor CM;
    Am Heart J; 2009 Oct; 158(4 Suppl):S37-44. PubMed ID: 19782787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. N-terminal pro-brain natriuretic peptide is a useful marker to identify latent heart failure patients in older adults in a rural outpatient clinic.
    Hamagawa K; Kubo T; Nishimura K; Baba Y; Hirota T; Yamasaki N; Kitaoka H
    Geriatr Gerontol Int; 2017 Oct; 17(10):1648-1653. PubMed ID: 27860152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of predictive value of NT-proBNP, sST2 and MMPs in heart failure patients with different ejection fractions.
    Pan W; Yang D; Yu P; Yu H
    BMC Cardiovasc Disord; 2020 Apr; 20(1):208. PubMed ID: 32354356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PATHFAST NT-proBNP (N-terminal-pro B type natriuretic peptide): a multicenter evaluation of a new point-of-care assay.
    Zaninotto M; Mion MM; Di Serio F; Caputo M; Ottomano C; Plebani M
    Clin Chem Lab Med; 2010 Jul; 48(7):1029-34. PubMed ID: 20406130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NT-proBNP in monitoring treatment of patients with congestive heart failure.
    Al-Meslmani BM; Fahoum SK; Shamia MG
    Clin Lab; 2007; 53(1-2):35-9. PubMed ID: 17323823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute cardiac dyspnea in the emergency department: diagnostic value of N-terminal prohormone of brain natriuretic peptide and galectin-3.
    Stoica A; Şorodoc V; Lionte C; Jaba IM; Costache I; Anisie E; Tuchiluș C; Rusalim Petriș O; Sîrbu O; Jaba E; Ceasovschih A; Vâţă L; Şorodoc L
    J Int Med Res; 2019 Jan; 47(1):159-172. PubMed ID: 30222016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data.
    Masson S; Latini R; Anand IS; Vago T; Angelici L; Barlera S; Missov ED; Clerico A; Tognoni G; Cohn JN;
    Clin Chem; 2006 Aug; 52(8):1528-38. PubMed ID: 16777915
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Molar Ratio of N-terminal pro-B-type Natriuretic Peptide/B-type Natriuretic Peptide for Heart Failure-related Events in Stable Outpatients with Cardiovascular Risk Factors.
    Suzuki S; Sugiyama S
    Intern Med; 2018 Sep; 57(18):2621-2630. PubMed ID: 29709934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.
    Ezekowitz JA; O'Connor CM; Troughton RW; Alemayehu WG; Westerhout CM; Voors AA; Butler J; Lam CSP; Ponikowski P; Emdin M; Patel MJ; Pieske B; Roessig L; Hernandez AF; Armstrong PW
    JACC Heart Fail; 2020 Nov; 8(11):931-939. PubMed ID: 33039447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pro-B-type natriuretic peptide levels in acute decompensated heart failure.
    Waldo SW; Beede J; Isakson S; Villard-Saussine S; Fareh J; Clopton P; Fitzgerald RL; Maisel AS
    J Am Coll Cardiol; 2008 May; 51(19):1874-82. PubMed ID: 18466803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Old markers, new approach to assessment of risk in heart failure.
    Kodziszewska K; Leszek P; Korewicki J; Piotrowski W
    Kardiol Pol; 2015; 73(6):387-95. PubMed ID: 25563469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations-Results From TIME-CHF.
    Davarzani N; Sanders-van Wijk S; Karel J; Maeder MT; Leibundgut G; Gutmann M; Pfisterer ME; Rickenbacher P; Peeters R; Brunner-la Rocca HP
    J Card Fail; 2017 May; 23(5):382-389. PubMed ID: 28232046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma NT-proBNP as a more reliable biomarker of endogenous cardiac natriuretic peptides than BNP during carperitide infusion.
    Nishiyama K; Tsutamoto T; Tanaka T; Fujii M; Yamamoto T; Yamaji M; Horie M
    Int Heart J; 2009 Mar; 50(2):183-90. PubMed ID: 19367029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amino-terminal pro-B-type natriuretic peptide testing for inpatient monitoring and treatment guidance of acute destabilized heart failure.
    Bettencourt P; Januzzi JL
    Am J Cardiol; 2008 Feb; 101(3A):67-71. PubMed ID: 18243862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Biomarkers in heart failure: BNP and NT-proBNP].
    Ho CC; Liu CC
    Hu Li Za Zhi; 2009 Oct; 56(5):16-22. PubMed ID: 19760573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction.
    Januzzi JL; Ahmad T; Mulder H; Coles A; Anstrom KJ; Adams KF; Ezekowitz JA; Fiuzat M; Houston-Miller N; Mark DB; Piña IL; Passmore G; Whellan DJ; Cooper LS; Leifer ES; Desvigne-Nickens P; Felker GM; O'Connor CM
    J Am Coll Cardiol; 2019 Sep; 74(9):1205-1217. PubMed ID: 31466618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Values of brain natriuretic peptide and N-terminal pro-brain natriuretic peptide in evaluation of cardiac function in children with congenital heart disease].
    Zhang SR; Zhang YH; Xu Q; Qiu HX; Chen Q
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jun; 11(6):429-32. PubMed ID: 19558803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarker responses during and after treatment with nesiritide infusion in patients with decompensated chronic heart failure.
    Miller WL; Hartman KA; Burritt MF; Borgeson DD; Burnett JC; Jaffe AS
    Clin Chem; 2005 Mar; 51(3):569-77. PubMed ID: 15615816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction.
    Daubert MA; Yow E; Barnhart HX; Piña IL; Ahmad T; Leifer E; Cooper L; Desvigne-Nickens P; Fiuzat M; Adams K; Ezekowitz J; Whellan DJ; Januzzi JL; O'Connor CM; Felker GM
    J Am Heart Assoc; 2021 May; 10(10):e019712. PubMed ID: 33955231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.